JMJD6 and renal cell carcinoma: Considering that JMJD6 interacts with BRD4 to form SEs, we treated RCC cells with a BRD4 inhibitor and found that JQ1 largely reduced VEGFA levels in a dose‐dependent manner (Figure 6H).